First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age

Line M Lindgren, Pernille N Tingskov, Annette H Justesen, Bettina S Nedergaard, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Charlotte Sørensen, Jes Dietrich, Birgit Thierry-Carstensen, Line M Lindgren, Pernille N Tingskov, Annette H Justesen, Bettina S Nedergaard, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Charlotte Sørensen, Jes Dietrich, Birgit Thierry-Carstensen

Abstract

Background: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans.

Methods: 240 Danish adolescents, aged 10-15years, and childhood vaccinated with IPV were booster vaccinated with 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al or IPV Vaccine SSI. The booster effects (GMTRs) of the three IPV-Al SSI were compared to IPV Vaccine SSI, and evaluated for non-inferiority.

Immunogenicity results: The pre-vaccination GMTs were similar across the groups; 926 (type 1), 969 (type 2) and 846 (type 3) in the total trial population. The GMTRs by poliovirus type and IPV formulation were: Type 1: 17.0 (1/3 IPV-Al), 13.0 (1/5 IPV-Al), 7.1 (1/10 IPV-Al) and 42.2 (IPV Vaccine SSI). Type 2: 12.5 (1/3 IPV-Al), 13.1 (1/5 IPV-Al), 7.6 (1/10 IPV-Al) and 47.8 (IPV Vaccine SSI). Type 3: 14.5 (1/3 IPV-Al), 16.2 (1/5 IPV-Al), 8.9 (1/10 IPV-Al) and 62.4 (IPV Vaccine SSI) Thus, the three IPV-Al formulations were highly immunogenic, but inferior to IPV Vaccine SSI, in this booster vaccination trial.

Safety results: No SAE and no AE of severe intensity occurred. 59.2% of the subjects reported at least one AE. Injection site pain was the most frequent AE in all groups; from 24.6% to 43.3%. Injection site redness and swelling frequencies were<5% in most and<10% in all groups. The most frequent systemic AEs were fatigue (from 8.2% to 15.0%) and headache (from 15.0% to 28.3%). Most AEs were of mild intensity. In conclusion, the three IPV-Al SSI were safe in adolescents and the booster effects were satisfactory. ClinicalTrials.gov registration number: NCT02280447.

Keywords: Affordable IPV; Aluminium hydroxide adjuvant; Dose investigation; IPV dose sparing.

Copyright © 2016. Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Disposition of subjects. The safety analysis set (SAF) was defined as randomised subjects who received a trial vaccination. The full analysis set (FAS) was defined as subjects who received a trial vaccination and had a post baseline immunogenicity measurement. The per protocol population (PP) was defined as the FAS with no major protocol deviations. All 240 subjects were included in the SAF, FAS and PP.
Fig. 2
Fig. 2
Scatter plots of poliovirus type 1 antibody log 2(titres) for 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al and the comparator IPV Vaccine SSI. The post-vaccination log 2(titre) of the individual subjects are plotted on the y-axis versus the pre-vaccination log 2(titre) on the x-axis. The seroprotection cut-off level (a titre ⩾ 8) in normal scale corresponds to a log 2(titres) ⩾ 3.
Fig. 3
Fig. 3
Scatter plots of poliovirus type 2 antibody log 2(titres) for 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al and the comparator IPV Vaccine SSI. The post-vaccination log 2(titre) of the individual subjects are plotted on the y-axis versus the pre-vaccination log 2(titre) on the x-axis. The seroprotection cut-off level (a titre ⩾ 8) in normal scale corresponds to a log 2(titres) ⩾ 3.
Fig. 4
Fig. 4
Scatter plots of poliovirus type 3 antibody log 2(titres) for 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al and the comparator IPV Vaccine SSI. The post-vaccination log 2(titre) of the individual subjects are plotted on the y-axis versus the pre-vaccination log 2(titre) on the x-axis. The seroprotection cut-off level (a titre ⩾ 8) in normal scale corresponds to a log 2(titres) ⩾ 3.

References

    1. World Health Organisation. Polio eradication & endgame strategic plan 2013-2018. WHO Press World Health Organisation, 20 Avenue Appia, Geneva, Switzerland 2013. Available from: URL: <>.
    1. Okayasu H., Sutter R.W., Jafari H.S., Takane M., Aylward R.B. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;1(210 Suppl 1):S459–S464. [November]
    1. Estivariz C.F., Pallansch M.A., Anand A. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013;3(3):309–315. [June]
    1. Brenzel L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Vaccine. 2015;7(33 Suppl 1):A93–A98. [May]
    1. Introduction of inactivated poliovirus vaccine and switch from trivalen to bivalent oral poliovirus vaccine - worldwide, 2013–2016. MMWR Recomm Rep 2016 March 7. Vol. 64 (25). p. 699–702.
    1. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine. 2008;26(39):4978–4983. [September 15]
    1. Wilson J. The ethics of disease eradication. Vaccine. 2014;32(52):7179–7183. [December 12]
    1. Polio vaccines: WHO position paper, January 2014–recommendations. Vaccine, vol. 32(33); 2014. p. 4117–8 [July 16].
    1. Andreasen L.V., Hansen L.B., Andersen P., Agger E.M., Dietrich J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine. 2015;17(33):1873–1879. [February]
    1. Plotkin S.A., Liese J., Madhi S.A., Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines. 2011;10(7):981–1005. [July]
    1. Vergara R., Tregnaghi M., Ussher J. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164(6):377–382. [June]
    1. Haastrup E., Thierry-Carstensen B., Jensen A.M., Stellfeld M., Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells. Vaccine. 2004;22(8):958–962. [February 25]
    1. Pietrzyk J.J., Wysocki J., Pejcz J. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age. Vaccine. 2008;26(41):5296–5303. [September 26]
    1. Thierry-Carstensen B., Dalby T., Stevner M.A., Robbins J.B., Schneerson R., Trollfors B. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013;28(31):5178–5191. [August]
    1. Melnick J., Wenner H.A., Philips C.A. American public health association Inc.; Washington, DC: 1976. Enteroviruses. Diagnostic procedures for viral, rickettsial and chlamydial infections.
    1. Vidor E, Plotkin S. Poliovirus vaccine - inactivated. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed.; 2013. p. 573–97.
    1. Aggerbeck H., Wantzin J., Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations–III. Vaccine. 1996;14(13):1265–1272. [September]
    1. Gajdos V., Vidor E., Richard P., Tran C., Sadorge C. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV. Vaccine. 2015;33(32):3988–3996. [July 31]
    1. Embree J., Law B., Voloshen T., Tomovici A. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clin Vaccine Immunol. 2015;22(3):282–290. [March]
    1. Bergfors E., Hermansson G., Nystrom K.U., Falk L., Valter L., Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr. 2014;173(10):1297–1307. [October]

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe